Immune checkpoint inhibitors (ICIs) have revolutionized therapeutic strategies in both oncology and autoimmune disorders by modulating immune system responses. These agents target key regulatory proteins, such
crucial biomarker in the field of oncology, particularly for predicting patient responses to immune checkpoint inhibitors (ICIs). TMB quantifies the number of mutations within a tumor’s DNA, reflecting
related skin rash is common in patients receiving PD-1/PD-L1-based immune checkpoint inhibitor therapy. This study aimed to explore whether development of rash is predicative of outcomes ... patients with non-small cell…
Immune Checkpoint Inhibitor (ICI) therapy is the most exciting development in cancer treatments in recent years. As of the end of 2021, more than a hundred of clinical trials have
therapies, including oral multitargeted Tyrosine Kinase Inhibitors (TKIs) and immune checkpoint inhibitors (IO), have significantly increased survival in the majority of patients with metastatic Renal Cell Carcinoma…
Immune checkpoint inhibitors have opened a new era in the treatment of advanced malignancies, resulting in increased use and remarkable clinical responses. However, there has been an increase
Immune checkpoint inhibitors enhance T cell response against malignant cells and are standard of care in many tumor types. Disinhibition of cytotoxic T cells in normal organs and inhibitrion
novel agent called checkpoint inhibitor therapy has revolutionized not only the treatment for several tumor entities but also our general understanding of oncology. As more and more patients with solid ... temporary…
osimertinib. Both patients had disease progression after osimertinib and received combination therapy of immune checkpoint blockade (nivolumab or pembrolizumab) and albumin-bound paclitaxel (Abraxane). These patients…
immunoedition, tumor microenviroment, immune privilege and the expression of the negative immune checkpoints which lead to an insufficient T cell activity and consequently cancer progression. After the approval of…
Blockade of the immune checkpoints has recently emerged as a paradigm shift in the treatment of solid tumors. Several programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte ... approved and are moving to…
Full-length cDNA of the gene checkpoint homolog 1 (Chk1) was cloned from Daphnia carinata and designated DcarChk1. DcarChk1 cDNA was 1817 bp in length and encoded a 497-amino
discovered frequent alterations in STAG2 and ESPL1 , two genes involved in the spindle checkpoint of the cell cycle. Furthermore, we also detected a recurrent fusion involving FGFR3 and TACC3 , another ... spindle…
oncology platform, enabling multiple distinct modalities including tumor starvation, enhanced apoptotic signaling and immune checkpoint inhibition, among others. Further studies are underway to evaluate the ability of…
progression of replication forks through challenging replication regions, restart of stalled forks, and replication checkpoint effectiveness have all received considerable attention to date. Pol k is also necessary…
Background: Neurological disorders are considered rare but severe complications of immune-checkpoint inhibitors. Case history: We report a 71-year-old man with metastatic renal cell cancer, who developed, confusional…
oncology field in the past decade. Specifically, drugs that block the immune checkpoints CTLA-4 or PD-1/PD-L1, known collectively as immune checkpoint inhibitors, have been approved ... treat over a dozen different…
neutralizing antibody also enhanced the efficacy of other cancer immunotherapeutic modalities, such as immune checkpoint blockade or cell-based therapy preclinically. Our study has launched a new avenue of cancer
For authors and organisers
Publish, present and keep up with your field
Find the right journal for your paper and submit your manuscript.